Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after
Carme Miret, Miren Orive, María Sala, Susana García‐Gutiérrez, Cristina Sarasqueta, María José Legarreta, Maximino Redondo, Amado Rivero, Xavier Castells, José M. Quintana, Olatz Garín, Montse Ferrer, the REDISSEC-CaMISS Group, Mercè Comas, Laia Domingo, Francesc Macià, Marta Román, Anabel Romero, Teresa Barata, Isabel Diez de la Lastra, Mariola de la Vega, Marisa Baré, Núria Torà, Joana Ferrer, Francesc Castanyer, Carmen Siavil Varguillas Carmona, Susana García‐Gutiérrez, M Martin, Nerea González, María Amparo Valverde, Alberto Ortiz Sáez, Inma Barredo, Manuel de Toro, J. Ferreiro, Jeanette Pérez, Cristina Rey Valcárcel, María del Carmen Padilla, Teresa Téllez, Irene Zarcos, Cristina Churruca, Amaia Perales, Javier Recio, Irune Ruiz, J.M. Urraca, M. Jesús Michelena, Júlio Moreno, Gaizka Mallabiabarrena, Patricia Cobos, Borja Otero, Javier Martínez Gorostiaga, Itsaso Troya
Abstract
PURPOSE: To obtain reference norms of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L, based on a population of Spanish non-metastatic breast cancer patients at diagnosis and 2 years after, according to relevant demographic and clinical characteristics. METHODS: Multicentric prospective cohort study including consecutive women aged ≥ 18 years with a diagnosis of incident non-metastatic breast cancer from April 2013 to May 2015. Health-related quality of life (HRQoL) questionnaires were administered between diagnosis and beginning the therapy, and 2 years after. HRQoL differences according to age, comorbidity and stage were tested with ANOVA or Chi Square test and multivariate linear regression models. RESULTS: 1276 patients were included, with a mean age of 58 years. Multivariate models of EORTC QLQ-C30 summary score and EQ-5D-5L index at diagnosis and at 2-year follow-up show the independent association of comorbidity and tumor stage with HRQoL. The standardized multivariate regression coefficient of EORTC QLQ-C30 summary score was lower (poorer HRQoL) for women with stage II and III than for those with stage 0 at diagnosis (- 0.11 and - 0.07, p < 0.05) and follow-up (- 0.15 and - 0.10, p < 0.01). The EQ-5D-5L index indicated poorer HRQoL for women with Charlson comorbidity index ≥ 2 than comorbidity 0 both at diagnosis (- 0.13, p < 0.001) and follow-up (- 0.18, p < 0.001). Therefore, we provided the reference norms at diagnosis and at the 2-year follow-up, stratified by age, comorbidity index, and tumor stage. CONCLUSION: These HRQoL reference norms can be useful to interpret the scores of women with non-metastatic breast cancer, comparing them with country-specific reference values for this population.